Has Imad Karam received payments from drug or device companies?

Yes. Drug and device makers reported $5,520 in general payments to Imad Karam across 111 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Imad Karam did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Imad Karam come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Imad Karam

Internal Medicine · Chesterfield, MONPI 1770193054

Payments from drug & device makers

$5,520in general payments, 2019–2025

Across 111 payments — averaging $49.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$867
AstraZeneca$642
Seagen Inc.$502
E.r. Squibb & Sons, L.L.C.$373
Daiichi Sankyo Inc.$331
Sanofi$291
plus $3K from 25 others

What the payments were for

Food & beverage$4,61084%
Education$91016%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson(2 entities)	15	$867
AstraZeneca(2 entities)	12	$642
Seagen Inc.	4	$502
E.r. Squibb & Sons, L.L.C.	6	$373
Daiichi Sankyo Inc.	11	$331
Sanofi	5	$291
Regeneron Healthcare Solutions, Inc.	6	$285
Pfizer	7	$278
Lilly USA, LLC	4	$263
Amgen	2	$250
Gilead	4	$245
AbbVie	2	$159
Eisai Inc.	2	$150
Exelixis Inc.	1	$131
Incyte Corporation	2	$126
Taiho Oncology, Inc.	5	$104
Bayer	3	$76
Puma Biotechnology, Inc.	3	$59
Sumitomo Pharma America, Inc.	2	$54
Novartis	2	$43
Bristol Myers Squibb	2	$41
Jazz Pharmaceuticals Inc.	1	$36
Karyopharm Therapeutics Inc.	1	$34
Genentech USA, Inc.	2	$31
Syndax Pharmaceuticals, Inc.	1	$27
Blueprint Medicines Corporation	1	$27
Servier Pharmaceuticals LLC	1	$24
Boehringer Ingelheim	1	$21
Otsuka America Pharmaceutical, Inc.	1	$18
GSK	1	$17
Array Biopharma Inc	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,520 in reported general payments places this provider in the 90th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri →

Other internal medicine in Chesterfield

Jianbo WangChesterfield$643K
Timothy SmithSaint Peters$21.4M
Craig DietzKansas City$4M
Michael ReschakSaint Louis$3.1M
Dima DandachiColumbia$1.2M
Santosh SharmaKansas City$782K
David PrelutskySaint Louis$575K
Danish JabbarSaint Louis$510K
Dubert GuerreroIndependence$369K
Hany SalamaSaint Louis$279K

See the full list for Missouri →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →